Last checked at 
Vela Technologies PLC - Bingley, England-based investment firm focused on technology - Findings from a clinical trial of a Covid-19 treatment for diabetics are encouraging. Vela, which has an economic interest in the AZD1656 asset, notes UK-based biomedical charity St George Street Capital reported the trial has been completed. St George Street Chair John Martin says: "The completion of the Clinical Study Report is a major milestone and we are encouraged by the trial findings which indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for Covid-19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge."
Current stock price: 0.055 pence, up 16% on Tuesday
Year-to-date change: down 29%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
